|Articles|August 16, 2016

Texas Reports First Locally-imported Zika Case

Author(s)Sarah Anwar

The El Paso resident is said to have contracted the infection while visiting Miami, Florida, where active Zika transmission has been confirmed

On Monday, August 15, 2016, the first ‘locally-imported’ Zika case was reported in El Paso, Texas. The patient is said to have contracted the infection while visiting Miami, Florida, where active Zika transmission has been confirmed.

The individual was tested for Zika after becoming ill upon returning from the trip. A press release from the Texas Department of State Health Services (DSHS) notes that this is to be classified as a ‘travel-associated’ Zika case, since the individual did not acquire infection in his or her state of residence. According to the DSHS, the infection was identified to have been acquired in Miami “after closely evaluating travel dates, symptom onset date and known local transmission of Zika virus in Miami. This will be El Paso County’s first Zika case, and the county has found no other evidence of the virus or local transmission.”

Today, the Florida Department of Health confirmed that the number of locally acquired Zika cases in the state is still 30. Currently, there have been a total of 108 international travel-related Zika cases reported in Texas as of yesterday; three of whom are pregnant women, two are congenitally-infected infants, and one who acquired the infection through sexual contact. Approximately one week ago, Texas reported its first Zika-related death, a congenitally-infected infant from Harris County who was diagnosed with microcephaly.

In addition to this, an increase of standing water due to a recent flood may cause a rise in the Zika vector population in another southern US state: Louisiana. As a result of the Amite River flood, which left tens of thousands of civilians stranded and at least nine dead, Louisiana Governor John Bel Edwards requested a federal emergency declaration, according to CNN. However, collateral damage is not the only repercussion of this historic flood. According to Governor Edwards, this flood will cause an increase in Aedes mosquito populations around the area. He said in an interview with CNN, “We’re going to have more than our share of mosquitoes. And with the Zika threat, we need assistance to spray for mosquitoes and for mosquito control and abatement. That is made available to us as a result of the declaration.”

Ben Beard, PhD, from the Centers for Disease control and Prevention (CDC), stated that the flood poses little threat in regards to the spread of Zika. This is because the vast amount of rain that caused the flood would also decrease the prevalence of disease-carrying mosquitoes in the area.

The Texas DSHS is advising all those who have traveled to Zika-endemic areas to take the necessary precautions to avoid infecting the local Zika vector population upon returning home to Texas. They recommend using EPA-approved insect repellent, covering exposed skin, using window and door screens at home, removing standing water in and around homes, and covering cans or containers where water can collect.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.